Zanzalintinib for Cancer

This trial tests a new treatment called zanzalintinib to determine its effectiveness in controlling recurrent or metastatic ONB cancer. The study also evaluates the treatment's safety for patients. Individuals with this specific cancer type, who have not received similar drugs and are unsuitable for surgery or radiotherapy, might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot take certain medications like oral anticoagulants and some complementary medicines close to the start of the trial. It's best to discuss your specific medications with the trial team.

Research has shown that zanzalintinib is generally well-tolerated by patients. Previous studies found its safety comparable to other treatments that target multiple pathways to inhibit blood vessel growth in tumors. While some side effects may occur, they are usually manageable and expected with this type of treatment.

In one study, combining zanzalintinib with another drug significantly reduced the risk of death compared to another treatment, highlighting its effectiveness and tolerability. Another study suggested that zanzalintinib might be safer than similar treatments like cabozantinib, which the FDA has already approved for other uses. This suggests that zanzalintinib could be a safer option for some patients.

Zanzalintinib is unique because it targets cancer cells with a novel mechanism that isn't addressed by many standard treatments like chemotherapy or radiation. Unlike most traditional therapies that can affect both healthy and cancerous cells, Zanzalintinib is designed to specifically target and inhibit pathways critical for cancer cell survival, potentially leading to fewer side effects. Researchers are excited about Zanzalintinib because its oral administration makes it more convenient for patients, and its targeted approach offers promise for more effective and personalized cancer treatment options.

This trial will evaluate Zanzalintinib as a standalone cancer treatment. Research has shown that Zanzalintinib, when combined with other treatments like atezolizumab, yields promising results in cancer studies. One study demonstrated that this combination extended patient survival to an average of 10.9 months, compared to 9.4 months with regorafenib. It also reduced the risk of death by 20% in some cases. The treatment shrank tumors in 63% of patients and stabilized or improved the disease in 90% of cases. These findings suggest that Zanzalintinib could effectively treat recurring or spreading cancers.²⁶⁷⁸⁹